Influenza Antibodies

x

Rationale

Influenza persists as a major threat to public health despite annual vaccination campaigns. The molecular mechanism of action of neutralizing antibodies and their specific interactions with virus surface proteins can guide the development of therapeutic options for longer-lasting immunity and a “universal vaccine”.

What we're doing

We have collaborated over the years with several laboratories (most recently with the EpiVax/INDIGO consortium) to contribute structural characterization and analysis of molecular interactions of various influenza antibodies. Our hope is that these molecular characterizations can support the development of next-generation influenza vaccines.

x

Publication Highlights

Avnir, Y.; Prachanronarong, K.L.; Zhang, Z.; Hou, S.; Peterson, E.C.; Sui, J.; Zayed, H.; Kurella, V.B.; McGuire, A.T.; Stamatatos, L.; Hilbert, B.J.; Bohn, M.-F.; Kowalik, T.F.; Jensen, J.D.; Finberg, R.W.; Wang, J.P.; Goodall, M.; Jefferis, R.; Zhu, Q.; Kurt Yilmaz, N.*; Schiffer, C.A.*; Marasco, W.A.* "Structural Determination of the Broadly Reactive Anti-IGHV1-69 Anti-idiotypic Antibody G6 and Its Idiotope” Cell Reports, Vol. 21, Iss. 11, pp. 3243-3255 (2017). (*joint corresponding author)

Prachanronarong KL, Canale AS, Liu P, Somasundaran M, Hou S, Poh YP, Han T, Zhu Q, Renzette N, Zeldovich KB, Kowalik TF, Kurt Yilmaz N, Jensen JD, Bolon DNA, Marasco WA, Finberg RW, Schiffer CA*, Wang JP*.  “Mutations in influenza A virus neuraminidase and hemagglutinin confer resistance against a broadly neutralizing hemagglutinin stem antibody” Journal of Virology, Vol. 93, Iss. 2, pp. e01639-18 (2019).